U.s. fda clears abbott's freestyle libre® 2 and freestyle libre® 3 sensors for integration with automated insulin delivery systems

Abbott's world's leading1 and affordable2 integrated continuous glucose monitoring (icgm) sensors are cleared for connectivity with automated insulin delivery (aid) systems in the u.s. sensors also cleared for use by children as young as two years old, for use by women with diabetes who are pregnant, and for wear time up to 15 days abbott park, ill., march 6, 2023 /prnewswire/ -- abbott (nyse: abt) today announced that the u.s. food and drug administration (fda) has cleared its freestyle libre 2 and freestyle libre 3 integrated continuous glucose monitoring (icgm) system sensors for integration with automated insulin delivery (aid) systems.
ABT Ratings Summary
ABT Quant Ranking